ile this under ‘The eyes have it.’

In a row that some doctors argue pits patient interests versus commercial interests, Novartis (NVS) and Bayer (BAYN) are threatening to take the U.K.’s National Health Service to court over plans to use a less-expensive drug for a serious eye condition that could save the agency millions of dollars.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The nhs never has has enough money to treat all the local population for its area ,so cheaper drugs doing the same thing saves money,im with them ,akthough in a lot of other areas nhs is wastful,do hiw u can demand u big pill giants demand they buy yours ,take a hike ,make yours cheaper ,inallaggy ,shopping nice jumer one shop 25 pounds next shop same jumper 20.98 where do u think ul buy it from ,take your expensive pills and take a hike

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.